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Immunomodulatory responses to the active form of vitamin D (1,25-dihydroxyvitamin
D, 1,25D) have been recognized for many years, but it is only in the last 5 years
that the potential role of this in normal human immune function has been recognized.
Genome-wide analyses have played a pivotal role in redefining our perspective on vitamin
D and immunity. The description of increased vitamin D receptor (VDR) and 1α-hydroxylase
(CYP27B1) expression in macrophages following a pathogen challenge, has underlined
the importance of intracrine vitamin D as key mediator of innate immune function. It
is now clear that both macrophages and dendritic cells (DCs) are able to respond to
25-hydroxyvitamin D (25D), the major circulating vitamin D metabolite, thereby providing
a link between the function of these cells and the variations in vitamin D status common
to many humans. The identification of hundreds of primary 1,25D target genes in immune
cells has also provided new insight into the role of vitamin D in the adaptive immune
system, such as the modulation of antigen-presentation and T cells proliferation and
phenotype, with the over-arching effects being to suppress inflammation and promote
immune tolerance. In macrophages 1,25D promotes antimicrobial responses through
the induction of antibacterial proteins, and stimulation of autophagy and autophagosome
activity. In this way variations in 25D levels have the potential to influence both innate
and adaptive immune responses. More recent genome-wide analyses have highlighted
how cytokine signaling pathways can influence the intracrine vitamin D system and either
enhance or abrogate responses to 25D. The current review will discuss the impact of
intracrine vitamin D metabolism on both innate and adaptive immunity, whilst introducing
the concept of disease-specific corruption of vitamin D metabolism and how this may alter
the requirements for vitamin D in maintaining a healthy immune system in humans.
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INTRODUCTION
Amongst the many reported extra-skeletal effects of vitamin D, its
ability to regulate immunity through effects on both the innate
and adaptive systems has received considerable attention. This
stems in part from homage to studies carried outmore than a cen-
tury ago by a then relatively unknown scientist, Dr. Nils Finsen. In
1903 Dr. Finsen won the Nobel Prize for Medicine or Physiology
for showing that he could cure the epidermal form of tubercu-
losis (TB), lupus vulgaris, using concentrated light irradiation
(Moller et al., 2005). The subsequent discovery that exposure to
ultra-violet light promotes epidermal synthesis of vitamin D led
to further studies describing the successful use of oral vitamin
D supplementation to treat lupus vulgaris, and other mycobac-
terial infections such as leprosy (Airey, 1946; Herrera, 1949). The
advent of antibiotic therapies for infectious diseases appeared to
have consigned these studies to the history books. However, in
2006 the work of Finsen returned to center stage as a consequence
of a series of genome-wide analyses that revealed pathogen-
induction of an intracrine vitamin D system in monocytes (Liu
et al., 2006), and an associated mechanism for anti-mycobacterial
actions of vitaminD (Wang et al., 2004), whilst also shedding light
on how these responses may vary according to the vitamin D “sta-
tus” of any given individual. With increasing awareness of vitamin
D-deficiency across the globe (Holick, 2007), and ongoing discus-
sions concerning the physiological and clinical relevance of this
(Holick et al., 2011; Ross et al., 2011), these genome-wide analy-
ses have played a pivotal role in defining our new perspective on
non-classical vitamin D physiology. The current review will detail
these developments and how they have helped to define a role for
vitamin D in normal immune function.
ANTIBACTERIAL RESPONSES TO VITAMIN D
Despite its early use in the treatment of mycobacterial dis-
eases such as TB and leprosy (Airey, 1946; Herrera, 1949), the
immunomodulatory actions of vitamin D did not become clear
until much later. Elucidation of this important non-classical
action of vitamin D stemmed from two key observations. Firstly,
most proliferating cells within the immune system express the
nuclear receptor for active 1,25-dihydroxyvitamin D (1,25D)—
the vitamin D receptor (VDR). Initial studies focused on 1,25D
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binding capacity in cells from the adaptive immune system such
as T and B lymphocytes (T and B cells) (Bhalla et al., 1983;
Provvedini et al., 1983), with subsequent reports describing spe-
cific intracellular binding of 1,25D in cells from the innate
immune system such as monocytes/macrophages (Kreutz et al.,
1993), dendritic cells (DC) (Brennan et al., 1987), neutrophils
(Takahashi et al., 2002), and monocytic cell lines (Mangelsdorf
et al., 1984). The functional significance of these data was not
immediately clear but, nevertheless, it was assumed that VDR-
expressing immune cells were able to respond the circulating
active 1,25D in a similar fashion to classical vitamin D target
tissues such as the intestine, kidney, and bone. However, this
assumption was challenged by the secondmajor observation link-
ing vitamin D and the immunity, namely the discovery of active
vitamin D metabolism by cells from the immune system.
Elevated serum levels of 1,25D reported for some patients with
the granulomatous disease sarcoidosis were shown to be due to
conversion of pro-hormone 25D to 1,25D by tissue and systemic
macrophages in these patients (Barbour et al., 1981; Adams et al.,
1983). Similar observations for other inflammatory and granu-
lomatous diseases (Kallas et al., 2010) suggested that immune
activity of the enzyme that catalyzes metabolism of 25D to 1,25D,
25-hydroxyvitamin D-1α-hydroxylase (1α-hydroxylase) was a
disease-related phenomenon. However, other studies, in vitro,
highlighting the potential for macrophage 1α-hydroxylase activ-
ity in the absence of disease (Koeffler et al., 1985; Reichel
et al., 1986) supported the exciting possibility that synthesis of
1,25D is part of normal immune function. Despite this, it was
another 20 years before evidence to support this proposal was
reported. Significantly, the major advances that provided this evi-
dence involved genome-wide strategies that explored both the
regulation and function of vitamin D by immune cells.
The first of the genome-wide studies to shed light on extra-
skeletal actions of vitamin D was published by John White and
colleagues at McGill University in Montreal and utilized a com-
bination of DNA array and in silico strategies. In this report,
DNA array analysis of 1,25D-regulated genes in squamous cell
carcinoma cells in vitro (Akutsu et al., 2001; Lin et al., 2002)
was combined with in silico analysis of genomic VDR binding
sites to provide a comprehensive overview of potential 1,25D-
VDR target genes (Wang et al., 2005). Genome-wide analysis of
DNA sequences that are able to bind liganded VDR revealed con-
sensus vitamin D response elements (VDRE) within the gene
promoters for two antibacterial proteins, cathelcidin (CAMP) and
β-defensin 2 (DEFB4) (Wang et al., 2005). Interestingly, although
both of these genes exhibited classical proximal promoter direct-
repeat 3 (DR3) consensus VDREs, only CAMP appeared to be
transcriptionally induced by 1,25D in monocytes (Wang et al.,
2005). The underlying mechanism for the differential regulation
of monocyte CAMP and DEFB4 by 1,25D was elucidated in sub-
sequent studies, the first of which described increased expression
of monocyte DEFB4 following co-treatment with 1,25D and the
inflammatory cytokine interleukin-1 (IL-1) (Liu et al., 2009).
Based on these observations and promoter analysis for the CAMP
andDEFB4 genes, it was concluded that transcriptional induction
of DEFB4 requires cooperative occupancy of nuclear factor-κB
(NF-κB) response elements as well as VDRE within the DEFB4
gene promoter. By contrast, induction of CAMP appears to be
primarily dependent on binding of VDR to promoter VDRE (Liu
et al., 2009). The importance of NF-κB and VDR as co-inducers
of DEFB4 transcription was further emphasized by studies of
the intracellular pathogen sensing protein NOD2 which is itself
transcriptionally induced by 1,25D (Wang et al., 2010b). Cells co-
treated with 1,25D and the ligand for NOD2, muramyl dipeptide
(MDP), a cell wall product of Gram-positive and Gram-negative
bacteria, showed potent NF-κB-dependent induction of DEFB4
(Wang et al., 2010b). In these studies expression of CAMP was
also enhanced by 1,25D-MDP co-treatment, suggesting that NF-
κB may cooperate with VDR in a variety of immunomodulatory
functions (Figure 1).
Subsequent functional studies confirmed that dose-dependent
vitamin D induction of CAMP transcription involves direct inter-
action between liganded VDR and VDRE in the CAMP gene
promoter (Wang et al., 2004; Gombart et al., 2005). Intriguingly,
the VDRE initially identified within the CAMP promoter appear
to be specific for subhuman and human primates, as there are
no similar motifs within equivalent genes for lower mammals
(Gombart et al., 2005). Acquisition of a VDRE by the CAMP
gene appears to have occurred following the introduction of an
FIGURE 1 | Mechanisms for induction of vitamin D-mediated
antibacterial responses in monocytes. Schematic representation of
monocyte/macrophage responses to infection with a pathogen such as
Mycobacterium tuberculosis (M. tb). Pattern recognition receptors (TLR2/1)
sense M. tb and signal to induce expression of 1α-hydroxylase (CYP27B1)
and the vitamin D receptor (VDR). The resulting intracrine system for
vitamin D (blue arrows) converts 25-hydroxyvitamin D (25D) to
1,25-dihydroxyvitamin D (1,25D), which then binds to VDR and promotes
transcriptional regulation. Prominent responses to intracrine activation of
vitamin D (pink arrows) include: induction of antibacterial cathelicidin
(CAMP) and β-defensin 2 (DEFB4); suppression of iron-regulatory hepcidin
(HAMP); promotion of autophagy; induction of NOD2 expression; feedback
regulation of toll-like receptor (TLR) expression; increased bacterial killing.
For some responses (e.g., induction of DEFB4) accessory immune signals
(MDP binding to NOD2, and IL-1 responsiveness) cooperate with intracrine
vitamin D via nuclear factor-κB (NF-κB) (green arrows).
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Alu short interspersed nuclear element (SINE) that placed CAMP
under the control of 1,25D-VDR (Gombart et al., 2009b). This
primate-specific adaptation has been conserved in humans and
apes as well as Old World and New World primates, suggest-
ing that a mechanism for transcriptional regulation of CAMP
by vitamin D confers biological advantages. The assumption is
that this mechanism will be potently activated by the relatively
high circulating levels of 25D and 1,25D that are characteristic
of non-human primates (Adams et al., 1985). A similar mecha-
nism would also have been advantageous in early Homo sapiens
whose existence is likely to have been defined by routine exposure
to ultra-violet light and increased cutaneous vitamin D produc-
tion, with associated high circulating levels of 25D. Conversely,
in modern man where serum 25D status is more variable, this
antibacterial mechanism may be less effective. Whilst this hypo-
thetical mechanism broadly supports beneficial innate immune
effects of vitamin D supplementation, the important question still
remaining is how variations in serum levels of inactive 25D are
able to influence immune responses driven by intracellular 1,25D
and VDR. The answer to this question has been pivotal to our per-
spective on the non-classical actions of vitamin D and was, again,
provided by genome-wide analyses.
For cells from both within and outside the classical immune
system, recognition of and response to pathogens involves surveil-
lance of pathogen-associated molecular patterns (PAMPs) by
pattern recognition receptors (PRR). Prominent amongst these
PRRs is the extended family of Toll-like receptor (TLR) non-
catalytic transmembrane receptors which interact with specific
PAMPs (Moresco et al., 2011). To clarify the role of the TLR2/1
heterodimer in mediating innate immune responses to the TB
pathogen, Mycobacterium tuberculosis (M. tb), Liu and col-
leagues carried out DNA array analysis of gene expression in
human macrophages and DCs following treatment with one of
the putative PRRs for M. tb (Liu et al., 2006). Amongst the
many macrophage genes shown to be differentially regulated
by 19 kDa lipoprotein (a TLR2-interacting PAMP), expression
of both CYP27B1 and VDR was increased (Liu et al., 2006)
(see Figure 1). This genome-wide approach provided the first
unbiased evidence of a role for vitamin D metabolism and sig-
naling in innate immune responses to a pathogen. Crucially,
the TLR2/1-stimulus induced expression of both CYP27B1 and
VDR, suggesting that macrophage responses to M. tb involve
an endogenous, intracrine, vitamin D system. Further studies
showed that macrophages co-treated with the TLR2/1-ligand,
19 kDa lipoprotein were responsive to both active 1,25D and
inactive 25D, confirming the functional efficacy of the intracrine
model. Moreover, inhibition of either 1α-hydroxylase activity, or
VDR function blocked the actions of 25D, underlining the impor-
tance of cell-specific metabolism as a determinant of vitamin D
immunoregulation.
The specific functional read-outs used in the TLR2/1-M.tb
study were induction of mRNA for the vitamin D catabolic
enzyme 24-hydroxylase (CYP24A1) and the antibacterial protein
CAMP (Liu et al., 2006). Parallel analysis of the other antibac-
terial target gene for 1,25D, DEFB4, did not reveal significant
induction of this gene in the presence of 19 kDa lipoprotein
and 25D. However, as outlined above, subsequent experiments
demonstrated that co-treatment with either IL-1 (Liu et al.,
2009), or the NOD2 ligand MDP (Wang et al., 2010b) coop-
erates with the TLR2/1 ligand and 25D to stimulate expression
of DEFB4. Antibacterial proteins such as CAMP and DEFB4
play a crucial role in vitamin D-mediated killing of intracellu-
lar bacteria. Monocytes treated with increasing concentrations of
CAMP peptide show a dose-dependent decrease in the viability
of internalized M. tb (Liu et al., 2006); a similar inhibition of
macrophage M. tb viability occurs in the presence of 25D, with
this effect being abrogated by a VDR antagonist. In other stud-
ies knockdown of either CAMP or DEFB4 decreased killing of
M. tb in macrophages, suggesting that both antibacterial pro-
teins are important in mediating vitamin D-induced responses
to mycobacterial infection (Liu et al., 2009). Both CAMP and
DEFB4 are detectable in the circulation where they are able to
support innate immune responses to extra-cellular pathogens
including anti-viral responses (Barlow et al., 2011; Tripathi et al.,
2013). However, pathogens such as mycobacteria are internal-
ized by phagocytosis, and bacterial killing can then take place
following fusion of the resulting phagosome with a lysosome to
form a phagolysosome. To evade this antibacterial process and
maintain intracellular viabilityM. tb can subvert the transition of
phagosomes to phagolysosomes (Vergne et al., 2004). In this situ-
ation, the host cell can restore pathogen encapsulation by evoking
alternative mechanisms such as autophagy, in which encapsula-
tion of organelles, cell proteins or intracellular pathogens in a
double-membrane autophagosome occurs prior to fusion with
lysosomes (Gutierrez et al., 2004). Although a well-recognized
feature of eukaryotic cells cytosolic homeostasis (Klionsky and
Emr, 2000), autophagy also appears to play a pivotal role in cel-
lular response to infection (Gutierrez et al., 2004; Deretic and
Levine, 2009). The ability of 1,25D and its synthetic analogs to
promote autophagy is well established (Hoyer-Hansen et al., 2005;
Wang et al., 2008), but recent data suggest that induction of
autophagy may be particularly important for vitamin D-induced
antibacterial responses to M. tb infection (Yuk et al., 2009; Shin
et al., 2011) (Figure 1). The precise mechanism for this is not
clear and may involve inhibition of the mammalian target of
rapamycin (mTOR) intracellular signaling system (O’Kelly et al.,
2006; Lisse et al., 2011) with mTOR acting to suppress the induc-
tion of autophagy (Sanjuan et al., 2009). It has also been suggested
that vitamin D-induced autophagy occurs via an indirect mecha-
nism, in that RNA-interference (RNAi) knockdown of antibacte-
rial CAMP was sufficient to abrogate 1,25D-induced autophagy
in monocytes (Yuk et al., 2009). In common with effects on
expression of antibacterial proteins, it was noted that mono-
cyte autophagy following activation of TLR2/1 involves enhanced
expression of VDR and CYP27B1 (Shin et al., 2011), further high-
lighting the importance of intracrine 25D metabolism and action
in normal human innate immunity.
Intracrine synthesis of 1,25D has also been shown to regulate
expression of another antibacterial protein, hepcidin antibacterial
protein (HAMP) (Bacchetta et al., 2013b). However, in contrast
to CAMP and DEFB4, the direct microbiocidal properties of
HAMP appear to be relatively weak. Instead, the major function
of HAMP appears to be suppression of the cell membrane pro-
tein ferroportin, the only known exporter of intracellular iron
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(Ganz, 2011). This link between HAMP and ferroportin in cells
such as enterocytes, hepatocytes and monocytes plays a key role
in the so-called anemia of infection or chronic disease (Ganz,
2009). Because pathogens such as bacteria utilize iron to maintain
growth, restriction of circulating iron concentrations provides
an important host response to systemic infection (Drakesmith
and Prentice, 2012). However, for pathogens such as M. tb that
attempt to evade immune surveillance at the intracellular level,
accumulation of iron within this environment may promote the
growth of internalized pathogens such as Salmonella typhimurium
(Nairz et al., 2007), M. tb (Schaible et al., 2002; Sow et al., 2007,
2009), and Chlamydia psittaci (Paradkar et al., 2008). Conversely,
innate immune and viral stimuli are known to stimulate the
expression of HAMP (Sow et al., 2009; Armitage et al., 2011).
In this setting suppression, rather than induction, of HAMP by
25D and 1,25D may be beneficial by abrogating HAMP-induced
suppression of ferroportin which, in turn, will favor iron export
and lower intracellular concentrations of iron. In studies carried
out by our group at UCLA, we have shown that 25D and 1,25D
suppress transcription of HAMP in monocytes and hepatocytes,
leading to increased membrane expression of ferroportin, and
decreased expression of ferritin (a surrogate biomarker for intra-
cellular iron concentrations) (Bacchetta et al., 2013b). Moreover,
in contrast to CAMP and DEFB4, elevated serum 25D levels (but
not 1,25D) following vitamin D supplementation of human sub-
jects in vivowere associated with potent suppression of circulating
concentrations of HAMP (Bacchetta et al., 2013b). It therefore
appears that regulation of the HAMP-ferroportin axis is another
key facet of vitamin D-mediated innate immune function, com-
plimentary to its reported effects on antibacterial proteins (Liu
et al., 2006; Adams and Hewison, 2008; Hewison, 2011), and
autophagy (Yuk et al., 2009; Shin et al., 2011) (see Figure 1).
However, it is important to recognize that the effect of vitamin
D on serum levels of hepcidin may have additional consequences
that are both positive (suppression of anemia) and negative
(decreased hepcidin for systemic infection). This may be partic-
ularly important for patients with chronic kidney disease (CKD)
who commonly present with impaired circulating levels of 25D
and 1,25D, and who are at higher risk of infection. In CKD,
low serum 25D has been shown to correlate inversely with ane-
mia (Lac et al., 2010) and directly with blood hemoglobin levels
(Kiss et al., 2011). These effects may be due to dysregulation of
normal HAMP-ferroportin function under conditions of vitamin
D-deficiency, further emphasizing the importance of vitamin D
supplementation in these patients.
Vitamin D may also target other innate immunity
mechanisms. For example, studies in vitro have shown that
1,25D promotes hyporesponsiveness to PAMPs by downregu-
lating expression of TLR2 and TLR4 on monocytes (Sadeghi
et al., 2006). In this way, vitamin D appears to promote feedback
control pathways that limit antibacterial activity and other innate
immune responses, thereby preventing potential inflammatory
events that arise from an over-elaboration of immune responses,
notably inflammatory T cell responses. Paradoxically, vitamin D
can also promote responses that amplify innate immune func-
tion. Recent studies have described 1,25D-mediated induction
of the triggering receptor on myeloid cells-1 (TREM-1) (Kim
et al., 2013), a cell surface protein associated with cytokine
and chemokine production (Bouchon et al., 2000) that can
also act to amplify TLR signaling (Bouchon et al., 2001). The
biological significance of this is still not clear and this mechanism
may be more important for cells such as neutrophils which are
the principal source of circulating CAMP. Neutrophils express
VDR but, unlike monocytes/macrophages, they do not appear
to express a functional 1α-hydroxylase and are therefore not
subject to intracrine activation of innate immune function. In
this setting, activation of proteins such as TREM-1 may help
to promote neutrophil responses to circulating 1,25D rather
than 25D through enhanced TLR-signaling. This, in turn, would
stimulate expression of VDR and sensitivity to 1,25D.
A similar cooperative TLR response has also been described
for epithelial keratinocytes, where basal expression of CYP27B1 is
insufficient to facilitate intracrine induction of antibacterial pro-
teins by serum 25D. However, following skin wounding, locally
generated transforming growth factor β (TGFβ) enhances expres-
sion of CYP27B1 (Schauber et al., 2007). The resulting TGFβ-
driven CYP27B1 expression is then able to stimulate intracrine
generation of antibacterial proteins such as CAMP to combat
potential infections associated with epidermal injury (Schauber
et al., 2007). Interestingly, the TGFβ-induced 1α-hydroxylase
activity was also associated with increased keratinocyte expres-
sion of TLR2 which further enhances surveillance of infectious
bacteria, but also suggests that the effects of vitamin D on TLR
expression are likely to be cell-specific. TGFβ and 1,25D may
also cooperate to promote expression of other pathways linked
to enhanced innate immune responses to infection such as induc-
tion of the enzyme 5-lipoxygenase (5-LO) that catalyzes synthesis
of leukotrienes. Expression of 5-LO in human monocytes is
induced by both 1,25D and TGFβ (Harle et al., 1998), with
1,25D enhancing expression of 5-LO through novel promoter-
independent VDRE within exons 10 and 12 and intronM of the
5-LO gene (Stoffers et al., 2010). Although commonly associ-
ated with bronchial dilation and asthma, leukotrienes are also
known to participate in leukocyte accumulation at sites of infec-
tion and phagocytosis of bacteria (Peters-Golden et al., 2005).
Leukotrienes have also been shown to trigger the processing of
antibacterial CAMP by neutophils (Wan et al., 2007).
Vitamin D-mediated innate immune responses may also be
species-specific. VDR-mediated induction of CAMP and DEFB4,
as well as suppression of HAMP, appears to be primate-specific;
other mammals may therefore utilize alternative innate immu-
nity targets for intracrine 1,25D. For example reactive oxygen
species (ROS) can be bacteriocidal; previous studies have shown
that macrophages infected with M. tb in the presence of 1,25D
produce high levels of the superoxide anion ROS via the NADPH
oxidase system (Sly et al., 2001). More recent studies have shown
that another ROS, nitric oxide (NO), is produced by mouse
macrophages as part of innate immune responses to infection,
with bacteriocidal consequences (Kohchi et al., 2009). The NO
pathway appears to play a pivotal role in mouse responses to M.
tb infection (Chan et al., 1992), but its importance to human
M. tb infection is less clear. Moreover, one study using 1,25D
and mouse macrophages has reported decreased expression of
the enzyme inducible nitric oxide synthase (iNOS) and its NO
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product, suggesting that the link between vitamin D and NO in
innate immune function is more complex than originally thought
(Chang et al., 2004). Irrespective of the antibacterial mechanism
that is utilized by animals such as mice, it is generally assumed
that vitamin D-mediated induction of these responses will occur
via the same intracrine monocyte mechanism that has been
described for humans. Although expression of CYP27B1 and 1α-
hydroxylase activity has been described for murine macrophages
in vitro (Esteban et al., 2004; Stoffels et al., 2007), the relative
importance of this in vivo is still unclear. Indeed recent studies
using the CYP27B1 KO mouse have suggested that CD8+ cyto-
toxic T cells are the predominant source of extra-renal 1,25D
within the murine immune system (Ooi et al., 2014). Further
studies are required to fully clarify the physiological importance
of this observation.
Genome-wide analyses and associated ex vivo and in vitro
experiments have clearly demonstrated the potential impor-
tance of vitamin D in maintaining optimal innate antibacterial
responses in humans. However, these studies have also prompted
three further crucially important questions: (1) how important
is vitamin D for the adaptive immune system? (2) can vitamin
D supplementation in vivo enhance these antibacterial responses?
(3) what happens to the vitamin D system in human immune dis-
eases? Each of these questions will be considered in the remaining
sections of this review.
VITAMIN D AND ANTIGEN PRESENTATION
In the seminal DNA array analysis of monocyte TLR2/1 responses
by Liu et al that highlighted induction of CYP27B1 and VDR by
M. tb, it was notable that DCs did not produce the same response
when challenged with 19 kDa lipoprotein, despite expressing
TLR2/1 (Liu et al., 2006). Monocytes/macrophages belong to
the same hematopoietic lineage as DCs, and both types of cells
are able to act as antigen-presenting cells (APCs) to promote
T cell and B cells responses. Furthermore like, monocytes, DCs
express VDR and CYP27B1, and exhibit an active intracrine vita-
min D system (Brennan et al., 1987; Fritsche et al., 2003; Hewison
et al., 2003). However, in contrast to monocytes/macrophages,
the primary function on intracrine vitamin D in DCs appears
to be as a regulator of cell maturation, and ability of DCs to
present antigen to T cells (Hewison et al., 2003). Differentiation
of DCs toward a mature APC is associated with increased expres-
sion of CYP27B1 but, paradoxically, a reciprocal decrease in VDR
(Hewison et al., 2003). It therefore seems likely that DCs will uti-
lize a paracrine vitamin D system, with immature DCs expressing
VDR and responding to 1,25D produced by mature DCs with
lower VDR expression. Such a mechanism may be biologically
advantageous in that it allows some DCs to mature and promote
T cell activation as part of normal adaptive immune responses,
whilst preventing an over-elaboration of this response that could
lead to inflammatory complications. A similar pattern of differ-
ential regulation of CYP27B1 and VDR has also been described
for monocytes differentiating toward macrophages (Kreutz et al.,
1993). The importance of 1,25D as a modulator of DC func-
tion is endorsed by studies of VDR and CYP27B1 knockout
mice, which present with lymphatic abnormalities consistent with
increased numbers of mature DCs (Griffin et al., 2001; Panda
et al., 2001) and dysregulated DC trafficking (Enioutina et al.,
2009).
In a similar fashion to macrophages, DCs can be divided into
distinct sub-types, specifically myeloid DCs (mDCs) and plas-
macytoid DCs (pDCs). These cells exhibit different cytokine and
chemokine profiles and exert complementary effects on T cells;
mDCs are efficient promoters of naïve T cell function (Liu, 2005),
whilst pDCs are more closely associated with attenuation of T
cell function (Steinman et al., 2003). In vitro, 1,25D preferen-
tially regulates mDCs, with associated suppression of naïve T cell
activation (Penna et al., 2007). However mDC and pDC express
similar levels of VDR, so tolerogenic pDC may also respond to
1,25D, possibly via local, intracrine mechanisms (Penna et al.,
2007). Alternatively, 1,25D generated by pDCsmay not act to reg-
ulate pDCmaturation but may, instead, act in a paracrine fashion
on VDR-expressing T-cells. The ability of vitamin D to influence
the differentiation and function of DCs provides another layer of
innate immune function that complements its antibacterial prop-
erties. However, this interaction between 1,25D and DC will also
have downstream effects on cells that interact with APCs, namely
cells from the adaptive immune system.
Consistent with the DNA array analyses that shed light
on the antibacterial function of vitamin D in monocytes
and macrophages (Liu et al., 2006), genome-wide analysis of
DCs has revealed diverse responses to vitamin D in these
cells. Proteomic analyses using matrix-assisted laser desorp-
tion/ionization (MALDI)-time of flight (TOF)/TOF strategies has
defined the key proteins associated with tolerogenic responses to
1,25D (Ferreira et al., 2012). Intriguingly, the dominant effect
of 1,25D treatment of monocyte-derived DCs described in this
study was the alteration of proteins associated with the cytoskele-
ton and metabolic function. The induction of cytoskeletal pro-
teins was shown to be consistent with DC responses to other
tolerogenic steroid hormones, such as glucococorticoids (Ferreira
et al., 2012). However, by contrast, the potent effects of 1,25D
on metabolic pathways in DCs appear to be distinct from the
effects of glucocorticoids. In particular, 1,25D induced signifi-
cantly more proteins associated with carbohydrate metabolism,
gluconeogenesis and the TCA cycle relative to the glucocorticoid
dexamethasone, whilst 1,25D and dexamethasone shared induc-
tion of other groups of proteins such as those associated with
glycolysis (Ferreira et al., 2012). This particular study also illus-
trates a key advantage of genome/proteome-wide analyses, which
is the ability to group changes in gene/protein expression accord-
ing to specific properties such as metabolism or cytoskeletal func-
tion. Moreover, more recent developments allow researchers to
utilize tools such as Ingenuity Pathway Analysis (IPA) or DAVID
to cluster altered genes and show protein or gene interaction net-
works (Hong et al., 2009). These “interactomes” provide a picture
of the cooperativity of responses to a particular cell treatment.
For example, recent proteomic analysis of responses to the syn-
thetic 1,25D analog TX527 in immature and mature DCs showed
that 65–75% of the proteins identified as TX527 responsive made
up a statistically significant interactome, with some commonality
between the two DC types (Ferreira et al., 2009). In this partic-
ular study the authors used multiple sets of data including the
Biomolecular InteractionNetworkDatabase (BIND) (Bader et al.,
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2003), and the Molecular Interaction Database (MINT) (Zanzoni
et al., 2002) to maximize potential interactions. The increasing
availability of gene/protein expression databases for different cell
types means that this type of strategy is likely to become a more
prominent feature of genome-wide expression analyses in the
future.
VITAMIN D AND ADAPTIVE IMMUNITY
As outlined above, one of the initial observations linking vitamin
D with the immune system was the presence of VDR in acti-
vated lymphocytes (Bhalla et al., 1983; Provvedini et al., 1983).
The development of lymphocytes takes place in the thymus with
VDR being expressed in medullary thymocytes but not in the less
mature cortical thymocytes (Ravid et al., 1984). However, once
cells leave the thymus and enter the circulation as T or B cells
VDR expression is lost until these cells are activated to proliferate
by mitogens (Bhalla et al., 1983; Provvedini et al., 1983). Indeed,
1,25D is a potent inhibitor of T-cell proliferation, blocking the
transition from early G1 phase to late G1 phase (Bhalla et al.,
1984; Nunn et al., 1986), but having no effect on transition from
Go (resting) to early G1 or from late G1 to S phase (Rigby et al.,
1985). Studies using T cells isolated from lymphatic tissue have
shown that expression of VDR and responsiveness to 1,25D is
proportional to the rate of cell proliferation (Karmali et al., 1991).
Although these early studies have highlighted a role for 1,25D as
a regulator of T and B cell proliferation, it has become increas-
ingly clear that the predominant effects of vitamin D on adaptive
immune function involve the modulation of T cell phenotype.
T cells consists of several sub-groups including cytotoxic
CD8+ T cells, natural killer cells, γδ T cells, memory cells, CD4+
helper T cells (Th cells), and regulatory T cells (Treg). The best
characterized vitamin D responses have been described for Th
cells, with 1,25D regulating T cell proliferation and cytokine
production (Lemire et al., 1985). Activation of naïve Th cells
by antigen and APCs generates pluripotent Th0 cells which can
then differentiate into further Th sub-groups based on distinct
cytokine profiles. Two of these sub-groups, Th1 (IL-2, IFNγ,
tumor necrosis factor alpha) and Th2 (IL-3, IL-4, IL-5, IL-10)
T cells, respectively support cell-mediated and humoral immu-
nity (Abbas et al., 1996; Romagnani, 2006). In vitro 1,25D inhibits
expression of Th1 cytokines (Lemire et al., 1995), whilst promot-
ing Th2 cytokines (Boonstra et al., 2001). More recently, other
Th cell sub-groups have been identified, including interleukin-17
(IL-17)-secreting T-cells (Th17 cells) and these cells are also tar-
gets for vitamin D. In the autoimmune disease-susceptible non-
obese diabetic (NOD) mouse treatment with 1,25D decreased
expression of IL-17 (Penna et al., 2006). In a similar fashion,
1,25D suppression of murine retinal autoimmunity involves inhi-
bition of Th17 activity (Tang et al., 2009).
In addition to its effects on Th cells, vitamin Dmay also act on
CD8+ cytotoxic T cells which express relatively high levels of VDR
(Rigby et al., 1987; Provvedini and Manolagas, 1989; Veldman
et al., 2000). As outlined above, CD8+ cells in mice have also
been reported to express the vitamin D-activating enzyme 1α-
hydroxylase (Ooi et al., 2014). CD8+ T cells are known to be
involved in autoimmune disease such as multiple sclerosis (MS)
(Babbe et al., 2000), but do not mediate the effects of 1,25D
in suppressing the murine form of MS, experimental autoim-
mune encepholmyelitis (EAE) (Meehan and DeLuca, 2002). More
recent studies have reported a link between vitamin D and a vari-
ant of CD8+ T cells, CD8αα cells. Unlike CD8+ T cells, CD8αα
cells are not cytotoxic andmay play a role in suppressing gastroin-
testinal inflammation (Cheroutre and Lambolez, 2008). VDR
knockout mice exhibit decreased numbers of CD8αα cells (Yu
et al., 2008), due to decreased T cell expression of the chemokine
receptor CCR9 preventing T cell homing to the gastrointestinal
tract. T cell homing defects provides a potential explanation for
the increased colonic inflammation observed in VDR knockout
mice when crossed with colitis disease-susceptible mice (Froicu
et al., 2003). Vitamin D metabolites may also influence T cell
homing in other tissues. In the skin, 1,25D stimulates expres-
sion of the chemokine receptor 10 (CCR10) which recognizes
the chemokine CCL27 secreted by keratinocytes (Sigmundsdottir
et al., 2007).
As well as acting as a modulator of Th cell phenotype and
function, vitamin D can also influence adaptive immunity by
promoting suppressor T cells known as regulatory T cells (Treg)
(Barrat et al., 2002). The precise mechanism by which vitamin
D regulates Tregs is still somewhat controversial. Initial studies
in vitro suggested that the ability of 1,25D to promote CD4+
CD25+ Treg was due to indirect effects on antigen-presenting
DCs, specifically suppression of DC maturation and increased
expression of DC cytokines such as CCL22 (Penna et al., 2007).
However, subsequent studies have also described direct effects of
1,25D on T cells to generate CTLA4-positive Treg (Jeffery et al.,
2009). Significantly, these studies were focused on the use of
active 1,25D as the immunomodulator, and it is only in more
recent studies that the role of pro-hormone 25D in Treg devel-
opment has been investigated (Jeffery et al., 2012). Data from this
study demonstrated the ability of 25D to promote the generation
of Treg through intracrine/paracrine effects on CYP27B1/VDR-
expressing DCs. Notably, this report also highlighted the impact
of vitamin D binding protein (DBP) on DC responses to 25D,
and concluded that non-DBP-bound (free) 25D is the form of
25D that is biologically active for generation of Tregs (Jeffery
et al., 2012). The importance of Treg as a facet of vitamin D
immunomodulation is illustrated by various studies in vivo. In
patients with CKD, systemic administration of 1,25D has been
shown to increase numbers of circulating Treg (Ardalan et al.,
2007). Conversely, in patients with MS, serum concentrations
of 25D correlate with Treg activity (Royal et al., 2009; Smolders
et al., 2009), underlining the importance of intracrine pathways
in mediating effects of vitamin D on adaptive, as well as innate
immunity. In mice, topical application of 1,25D (Gorman et al.,
2007) or its synthetic analog calcipotriol (Ghoreishi et al., 2009)
have been shown to increase numbers of Treg.
The effects of vitamin D on adaptive immunity have to date
been very much focused on its ability to modulate T cell prolif-
eration and phenotype. Nevertheless, early studies reported that
1,25D could also suppress the development of immunoglobulin
(Ig)-secreting B cells following mitogenic stimulation (Shiozawa
et al., 1985; Iho et al., 1986). Initial experiments suggested that
the most likely mechanism for this was an indirect effect through
inhibition of Th cells (Lemire et al., 1985), but more recent work
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has shown that 1,25D can suppress the differentiation of two types
of B cell, plasma cells and class-switched memory cells, through
apparent direct effects (Chen et al., 2007). Other reports have
shown that 1,25D can regulate B cell IL-10 (Heine et al., 2008)
and CCR10 (Shirakawa et al., 2008), suggesting that the effects of
1,25D on these cells is not restricted to their capacity to produce
immunoglobulin.
Although genome-wide screening has played a pivotal role
in identifying pivotal mechanisms for the interaction between
vitamin D and innate immunity, the same cannot be said for
vitamin D and adaptive immunity, where genome-wide analyses
have complemented an already well-established field of research.
Nevertheless, it is interesting to note reports where this strategy
has been applied. In some cases these analyses have revealed a role
for the vitamin D system, similar to the seminal studies of M. tb
induction of CYP27B1 and VDR. For example, transcriptional
profiling of γδT cells reported induction of VDR following activa-
tion of these cells with non-peptidic monoalkyl phosphate ligands
(Chen et al., 2005). This small sub-set of T cells plays an impor-
tant role in inflammatory diseases, and it was therefore speculated
that 1,25D may act to suppress these cells as part of a more gen-
eralized anti-inflammatory response. Further array analyses have
also identified VDR as one of a discrete number of genes involved
in the formation of B cell germinal centers (Nakayama et al.,
2006).
Array analyses have also been used to characterize the gene
regulatory effects associated with immunomodulatory responses
to 1,25D. These studies have focused primarily on the effects of
1,25D and its synthetic analogs on DCs, with results underlining
the ability of 1,25D to promote decreased antigen presentation
and a tolerogenic phenotype in these cells (Griffin et al., 2004;
Shen and Zheng, 2004; Pedersen et al., 2009; Szeles et al., 2009).
Notably, one of these array studies showed that the effects of
1,25D on DC gene expression were independent of DC differ-
entiation status, suggesting a specific role for 1,25D as a regu-
lator of DC function (Szeles et al., 2009). This particular study
also reported that key changes in DC gene expression could be
achieved using either 1,25D or 25D, further emphasizing the
functional importance of the intracrine vitamin D system in these
cells. DNA microarray analyses have also been used to assess
1,25D-mediated regulation of gene expression in CD4+ Th cells
following activation of these cells by phorbol myristate acetate
and a calcium ionophore to induce VDR (Mahon et al., 2003).
The diverse array of gene targets regulated by 1,25D in this par-
ticular array analysis suggests that 1,25D can influence Th cells
both directly, as well as via effects on antigen-presenting DCs.
VITAMIN D STATUS AND IMMUNE FUNCTION
It is important to recognize that most of the genome-wide
analyses that have explored the immunomodulatory effects of
vitamin D in vitro have focused on treatments using active
1,25D or one of its synthetic analogs. However, as outlined
above, pathogen-induction of an intracrine system in cells such
as monocytes/macrophages strongly suggests that regulation of
immunity in vivo is independent of endocrine, systemic 1,25D.
Instead it is likely to be primarily driven by local activation of
25D, the major circulating form of vitamin D and determinant
of vitamin D status in any given individual. Thus, it is not sur-
prising that translational studies have focused on the relationship
between serum 25D and human immune function, including
effects on both innate and adaptive immunity.
Epidemiology has shown that vitamin D-insufficiency (serum
25D <30 ng/ml) is associated with increased risk of TB
(Wilkinson et al., 2000; Ustianowski et al., 2005; Williams et al.,
2008; Wejse et al., 2009). Several clinical trials of vitamin sup-
plementation, as an adjunct to conventional antibiotic therapy,
have also been reported with varying success (Nursyam et al.,
2006; Martineau et al., 2007; Wejse et al., 2009). Supplementation
using 4× 100,000 IU vitamin D was successful in raising serum
concentrations of 25D in TB patients, but this resulted in no
overall improvement in sputum conversion time between vita-
min D- and placebo-treated patients (Martineau et al., 2011).
However, improved sputum conversion time was observed in a
specific subset of TB patients with a Taq1 single nucleotide poly-
morphism (SNP) within the VDR gene (Martineau et al., 2011),
suggesting that genetic factors may influence immune responses
to vitamin D supplementation. In a follow-up report to this
TB vitamin D supplementation trial, it was shown that raised
serum 25D was associated with improved resolution of TB dis-
ease (Coussens et al., 2012). Thus, in situations where infectious
disease has already become established, it is possible that the
role of 25D is primarily focused on anti-inflammatory adaptive
immune responses. The link between vitamin D and infection is
not restricted to TB. In patients with sepsis, circulating 25D levels
have been shown to correlate directly with serum concentrations
of CAMP, and inversely with critical illness in these patients (Jeng
et al., 2009). Low serum 25D has also been linked to upper respi-
ratory infections such as influenza (Cannell et al., 2006), and in
patients with CKD low serum is associated with increased risk of
infection and mortality (Gombart et al., 2009a).
To date, the application of genome-wide analyses to fur-
ther elucidate the impact of serum vitamin D (25D) status on
immune function has been limited. In a recent study by Holick
and colleagues, array analysis of gene expression in periph-
eral blood mononuclear cells from vitamin D-sufficient (serum
25D >20 ng/ml, n = 4 subjects) and vitamin D-deficient (serum
25D <20 ng/ml, n = 4 subjects) revealed 66 differentially
expressed genes (>1.5-fold change, p < 0.01) (Hossein-nezhad
et al., 2013). However, after vitamin D supplementation (2000
IU vitamin D/day for 2 months), there was no significant change
in the expression of these genes, even though serum 25D levels
were increased in both sufficient and deficient subjects (Hossein-
nezhad et al., 2013). Nevertheless, 291 additional genes were
found to be differentially expressed in peripheral blood mononu-
clear cells following vitamin D supplementation (>1.5-fold, p <
0.01) (Hossein-nezhad et al., 2013). Similar array analyses car-
ried out by our group using peripheral blood mononuclear cells
from elderly vitamin D-deficient (18.8 ± 0.6 ng/ml serum 25D)
and vitamin D–sufficient (58 ± 1.7 ng/ml serum 25D) patients,
revealed 30 differentially regulated genes (Figure 2). These varia-
tions in gene expression occurred against a backdrop of no differ-
ence in serum 1,25D concentrations between vitamin D-sufficient
and -deficient groups, underlining the importance of 25D, and
the intracrine vitamin D system as regulators of immune cell
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FIGURE 2 | Altered gene expression in leukocytes from vitamin
D-deficient donors. Peripheral blood mononuclear cells (PBMC) were
obtained from 6 healthy donors who had serum 25D levels that
were either low (47 nM, 18.8 ng/ml) or high (145 nM, 58 ng/ml). After
isolation of RNA and generation of cDNA, gene expression analyses
in the PBMC samples was carried out by DNA array analyses
(Affymetrix Exon Expr Chip.HuGene-1_0-st-v1). Data are shown as
genes that were either increased (red) or decreased (green) in low
25D donors relative to high 25D donors (>1.5-fold change, p < 0.05,
unpaired t-test).
function. In both this study and the Holick report, array analyses
were carried out using mixed populations of systemic immune
cells including both innate immunity APCs and lymphocytes of
the adaptive immune system. The array analyses will therefore
encapsulate both intracrine and paracrine activity of 25D, but will
also reflect inherent donor to donor variations in immune cell
composition.
Genome-wide analyses of immune responses to altered vita-
min D status in mice are also very limited. Data from our
group using colon tissue from vitamin D-deficient (serum 25D
= 2.5 ± 0.1 ng/ml) vs. vitamin D-sufficient (serum 25D =
24.4 ± 1.8 ng/ml) identified 31 genes that were differentially
expressed >2-fold (p < 0.01) (Lagishetty et al., 2010). Amongst
these, vitamin D-deficient mice showed decreased expression
of angiogenin-4 (Ang4), an antimicrobial protein which acts
to minimize tissue invasion by enteric bacteria (Hooper et al.,
2003). Further studies showed that decreased Ang4 in vitamin
D-deficient mice was associated with increased levels of bacte-
ria in the colon epithelium, consistent with compromised innate
immune surveillance. Given that dysregulation of innate immune
responses to enteric bacteria has been linked to the initiation of
tissue inflammation associated with some types of inflammatory
bowel disease (Packey and Sartor, 2009), it is possible that vitamin
D plays a role in protecting against this disease via the induction
of antibacterial Ang4.
Another genome-wide strategy with implications for vitamin
D and the immune system, arose from studies aimed at deter-
mining the genetic component of vitamin D-deficiency. A recent
Genome-Wide Association Study of almost 34,000 individuals
showed that SNPs within the DBP gene are a key inherited
determinant of low vitamin D status (serum 25D <75 nM or
30 ng/ml). Gene variations in DBP appear to act by influencing
the serum concentrations of DBP protein (Lauridsen et al., 2001)
which are known to be linked to serum levels of total 25D and
1,25D (Lauridsen et al., 2005;Wang et al., 2010a). Studies of other
DBP SNPs suggest that genetic variants of DBP are linked to dif-
ferent binding affinities of 25D for DBP protein (Arnaud and
Constans, 1993). Both the concentration and binding affinity of
DBP protein are important for the serum transport of vitamin
D metabolites (notably 25D which binds to DBP with a higher
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affinity than 1,25D). However, DBP concentration and affinity
also define the amount of 25D that is not bound to DBP. This
“free” or “bioavailable” fraction of circulating 25D appears to
be the form that accesses target cells such as monocytes (Chun
et al., 2012), presumably via passive diffusion of lipid-soluble 25D
through cell membranes—the so-called “free hormone hypothe-
sis.” Studies by our group have shown that antibacterial responses
to 25D in vitro are more pronounced with low affinity forms of
DBP that support higher levels of free 25D (Chun et al., 2010).
Studies to date have been based on mathematical estimations
of free 25D from total serum concentrations of 25D and DBP
(Chun et al., 2012). However, future strategies using actual phys-
ical measurement of free 25D will greatly help to clarify the
precise importance of total vs. free 25D in determining immune
responses to vitamin D.
IMMUNE DISEASE AND THE DYSREGULATION OF
VITAMIN D
Genome-wide strategies have played a pivotal role in elucidat-
ing the core mechanisms that trigger the intracrine vitamin D
system and associated immune responses in cells such as mono-
cytes/macrophages and DCs. Whether these studies have been
carried out using freshly isolated preparations of immune cells,
or cultured immune cells the resulting data have reflected the
potential vitamin D-mediated responses that may occur follow-
ing a pathogen challenge. What is less clear is how these responses
function under conditions of actual human immune disease. An
illuminating example of this strategy is provided by the disease
leprosy which, like TB, involves a mycobacterial infection—in this
case Mycobacterium leprae (M. lep) or Mycobacterium leproma-
tis. Similar to TB, vitamin D was at one time considered to be a
putative therapy for leprosy (Herrera, 1949). However, unlike TB,
leprosy can be divided into different disease sub-types, notably
tuberculoid leprosy (T-lep) and lepromatous leprosy (L-lep).
These two forms of leprosy have very different immune profiles
and prognoses (Britton and Lockwood, 2004). DNA array anal-
yses to define the gene expression profiles associated with the
T-lep and L-lep forms of leprosy, highlighted elevated expres-
sion of CYP27B1, CYP24A1, and VDR in T-lep vs. L-lep lesions
(Montoya et al., 2009). The over-arching conclusion from these
studies is that the less aggressive form of leprosy, T-lep, is man-
ifested by an intact vitamin D intracrine system that is able
to support antibacterial responses to vitamin D. By contrast,
L-lep, which is characterized by a high level of macrophage M.
lep infection, and has a poor prognosis, exhibits an impaired
vitamin D intracrine system. Thus, for patients with L-lep, suc-
cessful elevation of serum 25D concentrations may be less effec-
tive in promoting intracrine-mediated regulation of antibacterial
responses.
Several questions have arisen from the studies of vitamin D
and leprosy. The first concerns the mechanism by which the
vitamin D intracrine system is corrupted in L-lep patients. One
possibility is that the T cell cytokine profiles that are charac-
teristic of L-lep (e.g., increased IL-4, IL-10, and IFNα/β) exert
a detrimental adjunct effect on the underlying TLR2/1-induced
intracrine vitamin D system. At the same time, cytokine pro-
files associated with T-lep (e.g., increased IFNγ) may have more
beneficial adjunct effects. Subsequent experiments in vitro sup-
port this hypothesis, with the Th1 cytokine IFNγ enhancing
TLR2/1-induced vitamin D-activation and associated antibacte-
rial activity (Edfeldt et al., 2010; Fabri et al., 2011). Conversely,
the L-lep cytokines IL-4 (Edfeldt et al., 2010), IFNβ (Teles et al.,
2013), and IL-10 (Teles et al., 2013) suppress antibacterial pro-
duction (Figure 3). The effect of IFNβ appears to be mediated
via IL-10 which acts to suppress expression of CYP27B1 (Teles
et al., 2013), whereas IL-4 appears to act by stimulating activ-
ity of the vitamin D catabolic enzyme CYP24A1 (Edfeldt et al.,
2010). The collective conclusion from these studies is that specific
human diseases are characterized by T cell cytokines that act to
either promote or corrupt the underlying pathogen-PRR-driven
vitamin D intracrine system. Cytokine profiles such as this have
also been described for active and inactive TB (Berry et al., 2010;
Maertzdorf et al., 2012), providing an additional perspective on
the varying success of vitamin D supplementation trials with this
disease. Disease itself may therefore play a fundamental role in
determining the efficacy of immunomodulatory vitamin D for
any given patient; for example, it is possible that for diseases such
as L-lep, higher levels of serum 25D will be required to achieve a
specific antibacterial response. This is clearly an important topic
for future research.
The differential regulation of the intracrine vitamin D pathway
in T-lep and L-lep has also provided a platform for genome-
wide analyses aimed at identifying factors other than T cell
cytokines that may be involved in corrupting monocyte vitamin
D responses. In a follow-up to the previous DNA array studies for
FIGURE 3 | Mechanisms for corruption of vitamin D-mediated
antibacterial responses in monocytes. Schematic representation of
monocyte/macrophage responses to infection with a pathogen such as
Mycobacterium tuberculosis (M. tb), and associated adjunct signals.
Positive effects on the vitamin D intracrine system include: induction of
CYP27B1 expression by cytokines such as interferon γ (IFNγ) and
interleukin-15 (IL-15). Negative effects include suppression of CYP27B1 by
IL-10 and IFNβ, and induction of 24-hydroxylase activity by IL-4. Fibroblast
growth factor 23 (FGF23) also suppresses CYP27B1 and microRNA-21
(miR-21) associated with some pathogen infections (e.g., M. leprae) can
suppress expression of CYP27B1 by degradation of RNA and/or translation.
The serum vitamin D binding protein (DBP) may also attenuate intracrine
vitamin D by restricting monocyte bioavailability of free 25D.
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leprosy, further array analysis of T-lep and L-lep tissues revealed
distinct patterns of microRNA (miRNA) expression in these tis-
sues (Liu et al., 2012). Recent studies have shown that miRNAs
play a key role in fine-tuning gene expression by interacting
with RNA to silence gene expression either by degrading tran-
scripts, or by blocking their translation (Ketting, 2011). In L-lep,
16 miRNAs were found to be differentially induced relative to
T-lep tissue, with miRNA-21 (miR-21) being the most prominent
of these (Liu et al., 2012). In the context of innate immu-
nity and leprosy, miR-21 may target several important mech-
anisms, including suppression of IL-1 expression which may,
in turn, attenuate intracrine induction of antibacterial DEFB4
(see Figure 3). However, importantly, miR-21 is also predicted
to interact with CYP27B1 mRNA and suppress activity of 1α-
hydroxylase and decrease localized synthesis of 1,25D. In vitro,
siRNA knockdown of miR-21 in M. lep infected monocytes,
restored CYP27B1 expression and 25D-mediated antibacterial
responses (Liu et al., 2012). Despite these observations, rela-
tively little is known about how miRNAs corrupt vitamin D
signaling in disease situations. Based on genome-wide in silico
analysis of miRNA target sequences, multiple miRNAs are pre-
dicted to influence the expression of proteins associated with
vitamin D metabolism and signaling (reviewed in Lisse et al.,
2013a). However, other than studies of miR-21, there have been
few studies to validate the predicted effects of miRNAs on the
vitamin D system. Analysis of ovarian granulosa and breast can-
cer cells has demonstrated increased expression of miR-125B in
these tissue, and a concomitant dysregulation of two of its targets,
VDR and CYP24A1 mRNAs (Mohri et al., 2009). It seems likely
that future studies will identify other miRNAs that modulate
the vitamin D intracrine system in immune cells under disease
conditions. Moreover, it is important to recognize that vitamin
D itself is a potent regulator of miRNAs. To date, these studies
have focused on cancer (Wang et al., 2009, 2011), and bone cells
(Lisse et al., 2013b), but similar future studies of 1,25D-regulated
non-coding RNAs in immune cells may provide an entirely new
perspective on the immunomodulatory actions of vitamin D.
Some important questions about human disease and the
immunomodulatory effects of vitamin D remain unanswered.
For example, it is still not clear why there is aberrant synthe-
sis of 1,25D by macrophages in granulomatous diseases (Kallas
et al., 2010). It is also unclear what effect, if any, viral pathogens
such as hepatitis C or HIV have on innate and adaptive immune
actions of vitamin D, although HIV infection of some cells has
been shown to suppress expression of VDR (Chandel et al., 2013).
Future studies of vitamin D and the immune system may also
explore non-traditional targets for immune regulation. For exam-
ple, patients with end-stage kidney disease who routinely use dial-
ysis are at high risk of infection and associated mortalities. These
patients are also commonly vitamin D-deficient (Zehnder et al.,
2007), and this may impair normal innate immune responses to
infection. However, as with TB and leprosy, additional disease
factors may act to further compromise the intracrine vitamin
D system in these patients. Notably, circulating levels of fibrob-
last growth factor 23 (FGF23), which plays a key role in the
endocrine regulation of phosphate homeostasis, are elevated very
early in kidney disease (Danziger, 2008; Isakova et al., 2011). One
of the important actions of FGF23 is to suppress renal produc-
tion of 1,25D through the suppression of CYP27B1 expression
(Shimada et al., 2004); in this way FGF23 acts as a counter-
point to parathyroid hormone which stimulates CYP27B1 and
renal 1,25D production. Until recently, the effects of FGF23 were
thought to be restricted to the mineral homeostasis endocrine
system. However, work by our group has shown that FGF23 can
also act on monocytes to suppress expression of CYP27B1 and
the intracrine induction of antibacterial proteins (Bacchetta et al.,
2013a). These data highlight a mechanism by which renal dis-
ease may compromise vitamin D-mediated immune function,
similar to that observed for cytokines associated with infectious
disease (see Figure 3). As well as providing an explanation for the
increased risk of infection in kidney disease patients, these results
also suggest a hitherto unrecognized link between the vitamin D
endocrine system and its intracrine immune counterpart.
PERSPECTIVES
For many years, the link between vitamin D and the immune sys-
tem was considered to be a non-classical response with only a
pathophysiological relevance. The advent of genome-wide analy-
ses has enabled a complete change in this perspective by providing
an unbiased picture of how the vitamin D system is induced by
pathogens, and how the resulting intracrine cellular machinery
can promote both innate and adaptive immune responses to the
pathogen. A key challenge going forward will be to relate these
mechanisms to patient vitamin D status, and this is likely to
herald a new wave of genome-wide analyses linked to placebo-
controlled vitamin D supplementation trials. Interpretation of
these studies is likely to be complex. Recent genome-wide anal-
ysis of patient tissues has shown that some immune diseases
are characterized by corruption of the vitamin D system, so
that conventional notions of vitamin D-sufficiency and vitamin
D-deficiency may be very different for patients with specific dis-
eases. A key objective for future studies will be to determine
whether vitamin D-mediated-immune function is also applicable
tomousemodels, where genome-wide screening will help to iden-
tify immune targets that are related to, or distinct from, human
data. Future studies will also need to better characterize disease
corruption of vitamin D responses. Screening for disease-specific
microRNAs will be particularly important to identify non-coding
RNAs that can target components of the intracrine vitamin D.
The current shift away from DNA array technology to RNAseq
strategies will help to achieve these new objectives in a single
genome-wide screen, at increasingly affordable prices.
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